employee
employee
Russian Federation
employee
employee
VAK Russia 3.1.24
CSCSTI 76.29
Resume. The use of memantine has long been the basis of modern symptomatic therapy for patients with moderate and severe dementia with Alzheimer's disease. At the same time, the effectiveness of the drug in the treatment of mild dementia in this pathology remains the subject of wide discussion.The purpose of this open-label observational study is to analyze the relationship between clinical, neuroimaging markers and response to memantine therapy in patients with mild Alzheimer's dementia. Materials and methods. 40 patients (66.7 [60.8; 71.5] years old) received memantine at a dose of 20 mg/day for 3 months. The MRI parameters (overall severity of cerebrovascular changes, Medial Temporal lobe Atrophy (MTA)), the results of the Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MCA), Addenbrooke's Cognitive Examination, revised (ACE-R), Interlocking finger test (IFT), Free and Cued questionnaires were analyzed Selective Reminding Test – Immediate Recall (FCSRT-IR), Global Rating of Change Scale (GROC), the presence and characterization of side effects. Multiple linear regression models with calculation of β-coefficients were used to analyze the relationship between the response to therapy and the main analyzed parameters. Results. A significant improvement in cognitive function according to a number of tests was recorded after 2 months of treatment (MoCA, IFT, MMSE). Significant improvement in the ACE-R questionnaire (78.4 ± 2.7 vs 83.1 ± 2.7 points) was noted after 3 months of therapy. No significant changes in FCSRT-IR values were recorded during the follow-up period. The majority of patients regarded the improvement from the therapy as "moderate" and "pronounced" (GROC: 26/65%). There was no refusal of further treatment due to the development of adverse events. The most significant factors influencing the success of memantine therapy were OVCI (-0.552 (-0.034–0.814), MTA (-0,417 (-0,015–0,811)), the presence of diabetes mellitus (0.481 (0.028–0.825)) and urinary disorders (-0,414 (-0,074–0,997)). Conclusions. Short-term use of memantine in the treatment of mild Alzheimer's type dementia is effective and safe. The presence of concomitant marked atrophy of the medial frontal lobe, significant cerebrovascular changes according to MRI data, as well as urinary disorders are negative predictors of successful treatment of cognitive disorders, while in patients with diabetes mellitus, the effectiveness of memantine treatment was more pronounced.
mild Alzheimer's type dementia, memantine, neuropsychological tests, magnetic resonance imaging, predictors of therapy effectiveness
1. Corey-Bloom J. The ABC of Alzheimer's disease: cognitive changes and their management in Alzheimer's disease and related dementias. Int Psychogeriatr. 2002;14 (Suppl. 1):51–75. doi:https://doi.org/10.1017/S1041610203008664.
2. Kumar A., Sidhu J., Lui F., Tsao J. Alzheimer Disease. 2024; In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
3. Billings L., Oddo S., Green K., McGaugh J., LaFerla F. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675–88. doi:https://doi.org/10.1016/j.neuron.2005.01.040.
4. Pocnet C., Rossier J., Antonietti J-P., von Gunten A. personality changes in patients with beginning Alzheimer disease. Can J Psychiatry. 2011;56:408–17. doi:https://doi.org/10.1177/070674371105600704.
5. Safiri S., Ghaffari Jolfayi A., Fazlollahi A., Morsali S., Sarkesh A., Daei Sorkhabi A., Golabi B., Aletaha R., Motlagh Asghari K., Hamidi S., Mousavi S., Jamalkhani S., Karamzad N., Shamekh A., Mohammadinasab R., Sullman M., Şahin F., Kolahi A. Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. Front Med (Lausanne). 2024; 16;11:1474043. doi:https://doi.org/10.3389/fmed.2024.1474043.
6. Klinicheskie rekomendacii. «Kognitivnye rasstroystva u lic pozhilogo i starcheskogo vozrasta". Rossiyskaya associaciya gerontologov, Rossiyskoe obschestvo psihiatrov, Vserossiyskoe obschestvo nevrologov; 2024.
7. Wu C-L., Lin T-J., Chiou G-L., Lee C-Y., Luan H., Tsai M-J., Potvin P., Tsai C. A systematic review of MRI neuroimaging for education research. Front Psychol. 2021;12:617599. doi:https://doi.org/10.3389/fpsyg.2021.617599.
8. Butler E., Mounsey A. Structural mri for the early diagnosis of Alzheimer disease in patients with MCI. Am Fam Phys. 2021; 103:273–4. doi:https://doi.org/10.1002/14651858.CD009628.pub2.
9. Fazekas F., Kleinert R., Offenbacher H., Schmidt R., Kleinert G., Payer F., Radner H., Lechner H. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993; 43(9):1683–1689. https://doi.org/10.1212/wnl.43.9.1683.
10. Doubal F, MacLullich A., Ferguson K., Dennis M., Wardlaw J. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke. 2010; 41(3):450–454. https://doi.org/10.1161/STROKEAHA.109.564914.
11. Lau K., Li L., Schulz U., Simoni M., Chan K., Ho S., Cheung R., Kuker W., Mak H., Rothwell P. Total small vessel disease score and risk of recurrent stroke: validation in 2 large cohorts. Neurology. 2017: 88(24):2260–2267. https://doi.org/10.1212/ WNL.0000000000004042.
12. Wahlund L., Julin P., Johansson S., Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry. 2000;69(5):630-5. doi:https://doi.org/10.1136/jnnp.69.5.630.
13. Folstein M., Folstein S., McHugh P. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98. doi:https://doi.org/10.1016/0022-3956(75)90026-6.
14. Ziad S. Nasreddine, Natalie A. Phillips, Valérie Bédirian, Simon Charbonneau, Victor Whitehead. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment (angl.) // Journal of the American Geriatrics Society. 2005; 53, 4: 695–699. doihttps://doi.org/10.1111/j.1532-5415.2005.53221.
15. Varako N.A., Arhipova D.V., Kovyazina M.S., Yusupova D.G., Zaycev A.B., Zimin A.A., Solomina A.V., Bundhun P., Ramchandani N.M., Suponeva N.A., Piradov M.A. Addenbrukskaya shkala ocenki kognitivnyh funkciy III (Addenbrooke’s cognitive examination III — ACE-III): lingvokul'turnaya adaptaciya russkoyazychnoy versii. Annaly klinicheskoy i eksperimental'noy nevrologii 2022; 16(1): 53–58. DOI: https://doi.org/10.54101/ACEN.2022.1.7.
16. Moo L., Slotnick S. Tesoro M., Zee D., Hart J. Interlocking finger test: a bedside screen for parietal lobe dysfunction Journal of Neurology, Neurosurgery & Psychiatry 2003;74:530-532.
17. Ivnik R., Smith G., Lucas J., Tangalos E., Kokmen E, Petersen RC. Free and cued selective reminding test: MOANS norms. J Clin Exp Neuropsychol. 1997;19(5):676-91. doi:https://doi.org/10.1080/01688639708403753.
18. Jaeschke R., Singer J., Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference // Control Clin. Trials. 1989; 10: 407-415. doihttps://doi.org/10.1016/0197-2456(89)90005-6.
19. Rebrova O. Statisticheskiy analiz medicinskih dannyh. Primenenie paketa prikladnyh programm STATISTISA // M.: MediaSfera, 2002. – 312 s.
20. Zhang N., Wei C., Du H., et al. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer’s Disease Patients. Dement. Geriatr. Cogn. Disord. 2015; 40(1–2): c. 85–93. doi:https://doi.org/10.1159/000430808.
21. Doody R., Tariot P., Pfeiffer E., Olin J., Graham S. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement. 2007;3(1):7-17. doi:https://doi.org/10.1016/j.jalz.2006.10.004.
22. McShane R., Westby M., Roberts E., Minakaran N., Schneider L., Farrimond L., Maayan N., Ware J., Debarros J.. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi:https://doi.org/10.1002/14651858.CD003154.
23. Matsunaga S., Kishi T., Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis PLoS One. 2015; 10, e0123289.
24. van der Putt R., Dineen C., Janes, D., Series H., McShane R. Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice. Int J Geriatr Psychiatry 2006; 21: 755–60. doi:https://doi.org/10.1002/gps.1557.
25. Wattmo C., Wallin Å., Minthon L. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort. BMC Neurol 2012; 12(1): 134. doi:https://doi.org/10.1186/1471-2377-12-134.
26. Vaci N., Koychev I., Kim C., Kormilitzin A., Liu Q., Lucas C., Dehghan A., Nenadic G., Nevado-Holgado A. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. Br J Psychiatry. 2021;218(5):261-267. doi:https://doi.org/10.1192/bjp.2020.
27. Swerdlow N., Kotz J., Joshi Y., Talledo J., Sprock J., Molina J., Huisa B., Huege S., Romero J., Walsh M., Delano-Wood L., Light G. Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration. J Alzheimers Dis. 2021;84(4):1431-1438. doi:https://doi.org/10.3233/JAD-215029.
28. Tang B., Wang Y., Ren J. Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications. Ibrain. 2023;6;9(3):340-348. doi:https://doi.org/10.1002/ibra.12098.
